Heron Therapeutics, Inc. (HRTX) financial statements and ratios from SEC XBRL: revenue $154.90M (TTM), net margin -13.0%, revenue growth 7.4% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $154.90M |
| Net Margin | -13.0% |
| Return on Equity | -492.9% |
| Current Ratio | 2.49 |
| Revenue Growth (YoY) | 7.4% |
| EPS Growth (YoY) | 33.3% |
| FCF Growth (YoY) | 15.2% |
| EV / EBITDA | -5.0 |
| Price / Book | 9.34 |
| Price / Sales | 0.43 |
| FCF Yield | -18.8% |
| Altman Z-Score | -9.18 (distress) |
| Sector P/E (Healthcare) | 21.7 |
HRTX overview · HRTX earnings · HRTX KPIs · HRTX investor relations · HRTX ownership · HRTX peers · HRTX filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.